Abstract
Introduction and hypothesis
We aimed to examine the risk of bleeding in female patients undergoing intravesical onabotulinumtoxinA (BTX-A) treatments and provide clinical recommendations for the perioperative management of patients on antithrombotic therapy prior to BTX-A treatments.
Methods
This was a retrospective cohort of Danish female patients, who had their first BTX-A treatment because of an overactive bladder at the Department of Gynecology and Obstetrics, Herlev and Gentofte University Hospital, between January 2015 and December 2020. Data extraction was from an electronic medical journal system. BTX-A, Botox® Allergan was injected in the detrusor at 10–20 sites. Significant bleeding during or after a BTX-A treatment was defined as persistent macroscopic hematuria. Bleeding reporting was based on information obtained from journal notes.
Results
We included 400 female patients, who had a total of 1,059 BTX-A treatments. Median age at first BTX-A treatment was 70 years (IQR 21), and median number of BTX-A treatments was 2 (range 1–11). In total, 27.8% (n=111) received antithrombotic therapy. Within this group, 30.6% and 69.4% were on anticoagulant and antiplatelet therapy. No cases of hematuria were reported in our cohort. We found that no patients stopped their antithrombotic therapy, were bridged, or monitored by International Normalized Ration (INR) levels.
Conclusions
We suggest that BTX-A treatments might be classified as low-risk procedures. Discontinuation of antithrombotic therapy is not required in the perioperative management of this patient group.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Intradetrusor onabotulinumtoxinA (BTX-A) injections are a well-established treatment for overactive bladder. The injections are performed intravesically with a needle in 10–20 sites in the detrusor under cystoscopic guidance [1]. More than 600 BTX-A treatments are performed yearly at our tertiary Urogynecology Clinic, Herlev and Gentofte University Hospital, and the number is increasing.
It is an invasive procedure that can potentially result in bleeding complications. The risk of perioperative bleeding, in general, is increased in patients of older age (>65 years), patients with cardiovascular and cerebrovascular diseases, abnormal renal or liver function, and on certain medicines [2, 3]. Risk assessment of bleeding complications involves an overall assessment of patient-related and procedure-related risks for thrombosis and bleeding [4]. Female patients referred for BTX-A treatments tend to be older, and older age is associated with cardiovascular and cerebrovascular diseases [5, 6] requiring antithrombotic therapy. The clinical management of antithrombotic therapy for patients who require an invasive procedure is a common challenge. To our knowledge, there are no guidelines on the management of patients on antithrombotic therapy undergoing BTX-A treatments. Cystoscopy is listed as a low-risk procedure, but other transurethral procedures, such as bladder biopsy, are listed as moderate-risk procedures, in which discontinuation of antithrombotic therapy is indicated [7]. In addition, bridging may be indicated depending on the antithrombotic agent [4]. However, the Danish Association on Thrombosis and Hemostasis, which conducts guidelines regarding bridging for surgical procedures, has not listed BTX-A injections in the currently available bridging application commonly used by Danish physicians [8]. No clear consensus exists on the approach to the perioperative management of antithrombotic therapy for patients undergoing BTX-A treatment, and updated recommendations are needed. Our study was aimed at examining the risk of bleeding in female patients undergoing intravesical BTX-A treatments and to provide clinical recommendations for the perioperative management of antithrombotic therapy. We hypothesized that the risk of bleeding requiring intervention might be low, and that discontinuation of antithrombotic therapy was not required.
Materials and methods
Approval of our retrospective cohort study was obtained from Capital Region’s Knowledge Center for Data reviews (ID: R-21013125). Data extraction of our cohort of female patients, who had their first BTX-A treatment at the Department of Gynecology and Obstetrics, Herlev and Gentofte University Hospital between January 2015 and December 2020, was from the Danish electronic medical journal system “Sundhedsplatformen” by a data specialist. Patient data including demographics, medical history, antithrombotic therapy and indication, number of BTX-A treatments, information on bridging, International Normalized Ratio (INR) monitoring, and bleeding reporting were reviewed. All collected data were stored in the online database Research Electronic Data Capture (REDCap).
Study population
Female patients over 18 years of age referred for treatment with BTX-A injections owing to an overactive bladder in our Urogynecology Clinic were identified.
BTX-A treatment
Patients were treated with BTX-A, Botox® Allergan. BTX-A was injected into the detrusor at 10–20 sites sparing the trigone under cystoscopic guidance. The treatments were performed in an operating theater or at our outpatient clinic, depending on the requirement for sedation during the injections.
Bleeding reporting
Significant bleeding during or after a BTX-A treatment was defined as persistent macroscopic hematuria. Easy bleeding from the injection sites may occur but usually ceases during the BTX-A injection procedure, causing no significant hematuria.
Patients undergoing BTX-A treatments are routinely informed to contact our outpatient clinic if they experience any adverse effects, including bleeding. Follow-up related to assessment of post-void residual volume is scheduled for some patients, whereas no specific follow-up of bleeding is scheduled routinely. Bleeding reporting was based on information obtained from journal notes in the medical records.
Patients on antithrombotic therapy were divided in two groups depending on the administered antithrombotic agent, anticoagulant (AC), and antiplatelet (AP) therapy respectively.
Statistical analysis
Descriptive statistics were performed in R Studio, version 2022.07.1. Age and number of treatments were reported in median, interquartile range (IQR), and range. In this analysis, we assessed rates of antithrombotic therapy, antithrombotic agents, and the primary outcome, bleeding.
Results
We included 400 consecutive female patients who had intravesical BTX-A treatments. Baseline characteristics are listed in Table 1. In total, 1,059 BTX-A treatments were performed during the study period. Median age at first BTX-A treatment was 70 years (IQR 21, range 19–92). The patients received between 1 and 11 BTX-A treatments with a median of 2 treatments (range 1–11). BTX-A treatment doses varied between 50 IU and 300 IU. In total, 27.8% (n=111) of patients received antithrombotic therapy during their first BTX-A treatment. Seven different antithrombotic agents were registered, as listed in Table 2. Within this group, 69.4% and 30.6% were on AP and AC therapy respectively. One patient (0.9%) administered dual AP therapy with aspirin and clopidogrel. Antithrombotic therapy indications included previous stroke, cardiovascular diseases, and prevention of thromboembolism. We found no reported cases of bleeding or hematuria. No patients were discontinued in their antithrombotic therapy, bridged, or monitored by INR levels.
Discussion
We found no cases of bleeding in a Danish retrospective cohort comprising 400 female patients, who underwent between 1 and 11 BTX-A treatments for an overactive bladder at our Urogynecology Clinic. Within this cohort, 27.8% of patients were on antithrombotic therapy. Our results demonstrate that BTX-A treatments constitute a low bleeding risk. A previous Cochrane review concluded that intravesical BTX-A treatments are safe, with few adverse effects and complications, thereby supporting our results [1]. Three of the studies included in the review each reported one case of hematuria in small populations [9,10,11]. One study reported a single subject experience of hematuria after placebo injection with saline, which after further investigation seemed to originate from ureteric varicosities [10]. Another study reported hematuria in a patient who received a suburothelial BTX-A injection [11]. Mensah et al. recently reported a hemorrhagic event in one male patient, requiring a 1-day treatment of a two-way urethral catheter, out of 114 patients on antithrombotic therapy in a cohort comprising 532 female and male patients. The patient was on nonvitamin K oral anticoagulant (NOAC) therapy with rivaroxaban and received BTX-A treatment with 300 U at 20 sites. Additional patient-related risk factors included a history of prostate radiotherapy and self-catheterization [12]. Our cohort is unique in only including female patients, as male patients have been reported to have hematuria rates between 1.3% and 29% [13].
We found that none of the patients in our cohort discontinued their antithrombotic therapy prior to BTX-A treatments, according to the medical record. A plausible explanation could be that the procedure in our department is considered safe from a clinical perspective. However, antithrombotic therapy challenges the perioperative management of this patient group, and international consensus on this clinical matter is lacking. Older patients on antithrombotic therapy are at a higher risk of thromboembolic events and complications, including bleeding [3], and discontinuation of antithrombotic therapy perioperatively could further contribute to these perioperative events [14, 15]. Previous studies reported an association between AC discontinuation and perioperative thromboembolic events, with reported rates up to 1.9% [14, 15]. In a study, recurrent stroke and cardiovascular event rates following discontinuation of the AP agents, aspirin plus extended-release dipyridamole (ASA + ERDP) or clopidogrel, were compared with event rates in an on-treatment population. The reported absolute excess risks of recurrent stroke within 30 days of discontinuation were 0.77% for ASA + ERDP and 0.40% for clopidogrel. The corresponding absolute risks of major vascular events were 1.83% and 2.02%. AP discontinuation after ischemic stroke should be advocated when the risk of bleeding outweighs the risk of cardiovascular events [16]. Therefore, a balanced risk assessment of the patient and procedure-related risk of bleeding and thromboembolism is important in managing antithrombotic therapy for patients referred for an invasive procedure. The European Society of Cardiology (ESC) has recently updated a guideline on the cardiovascular assessment and management of patients undergoing noncardiac surgery, including perioperative management of antithrombotic agents [4]. Patient risks include age, individual thrombotic risk, history of bleeding complications, renal function, concomitant medication, and comorbidity, whereas procedure-related risk factors include urgency of the intervention and the bleeding risks of the procedure [4]. The perioperative management of antithrombotic therapy depends on the administered antithrombotic agent. Seven different antithrombotic agents were administered in the cohort, of which 30.6% of patients were administered AC agents during their first BTX-A treatment. Generally, AC therapy discontinuation is not recommended prior to low-risk bleeding procedures and other procedures with easy bleeding control [17]. Low-risk bleeding procedures are recommended to be performed at trough levels (12 to 24 h after last intake of AC), scheduling the procedure at the start of the next dosing interval, in patients on NOAC therapy (direct thrombin inhibitor and direct factor Xa inhibitors) [4, 18]. Monitoring and maintenance of the INR at the lower level of the therapeutic range is recommended, particularly in patients with mechanical heart valves and on vitamin K antagonists [1, 17]. Conversely, guidelines on the perioperative management of patients undergoing urological surgery recommend discontinuation of the vitamin K antagonist warfarin 3–5 days prior to the procedure for patients who are at a low risk for thromboembolism [19].
Among patients on antithrombotic therapy, we found that 69.4% were administered AP agents. The ESC recommends that continuation of the AP agent aspirin should depend on the perioperative bleeding risk compared with the risk of thrombotic complications [17]. Guidelines on perioperative AP management in patients undergoing minor procedures are lacking [20]. A previous randomized trial reported no significant difference in the risk of a major thromboembolic event and bleeding, whether low-dose aspirin was continued or discontinued in 291 patients with cardiac risk factors who underwent noncardiac surgery. The trial included 45 unspecified urological major surgeries [21]. The American Urological Association recommends continuation of low-dose aspirin in patients undergoing prostatic biopsies, based on a slightly increased bleeding risk [22]. This is supported by a recent meta-analysis, that reported no increased risk of hematuria after a prostate biopsy. However, a risk of postoperative rectal bleeding was reported [23]. Transurethral resections of bladder tumors have been reported to be safe concerning bleeding, as a previous retrospective cohort study found no increased risk of severe bleeding. However, an increased risk of postoperative clot retention was reported. Results were based on a small female and male population, including 19 on antithrombotic therapy, 18 discontinuing antithrombotic therapy, and 137 in the control group [24]. We can argue that BTX-A treatments are less invasive than a prostate biopsy procedure and transurethral resection of bladder tumors, emphasizing that BTX-A treatments may be considered a low-risk procedure.
For the prevention of a perioperative thromboembolism during discontinuation of AC therapy, a bridging therapy strategy can be used. Bridging therapy refers to the use of short-acting ACs, including unfractionated heparin or low-molecular-weight heparin [25]. We found that none of the patients in our cohort was bridged. Bridging benefits in patients are open to debate because of an increased risk for stroke owing to AC discontinuation, whereas bridging may cause a higher bleeding risk without necessarily protecting against thromboembolism [22, 26, 27]. On the contrary, international urological guidelines recommend bridging therapy before surgery or when the INR is lower than 2.0 in patients on warfarin therapy [19]. INR monitoring was not performed in our patient cohort. INR monitoring is essential for patients on warfarin therapy, whereas monitoring INR in patients on NOACs is not required owing to different pharmacokinetics [28].
The bleeding risk associated with BTX-A treatments is not well described, and to our knowledge no guideline is available on the management of patients on antithrombotic therapy undergoing this procedure, emphasizing the need for recommendations.
Based on our findings and the available literature, we suggest that BTX-A treatments might be classified as low-risk surgical procedures with regard to bleeding complications. As the benefits of antithrombotic therapy are likely to outweigh the risk of bleeding, demonstrated by no reported bleeding case in our cohort, we suggest continuing antithrombotic therapy in female patients undergoing a BTX-A treatment. BTX-A treatments are frequently performed at our Urogynecology Clinic, and the number is increasing. Our results can support the development of a clinical practice guideline concerning the perioperative management of antithrombotic therapy, including counseling, in this patient group. Nevertheless, physicians should assess patients individually in the case of a history of procedure-related bleeding.
In the event of bleeding, treatment is accessible. Common treatments of hematuria in urogynecological patients include urethral catheterization with a two-way catheter and saline bladder irrigation. Bleeding management at the operating theatre could be indicated in the case of failed conservative treatment, or a hemodynamically unstable patient.
Our study has some limitations. We may have underestimated the bleeding risk and missed some cases of bleeding, as any events relied on self-reporting from the patients. Patients are informed to contact the Urogynecology Clinic in the event of bleeding. No systematic reporting or follow-up on bleeding has been established. The retrospective nature of the study contributes to limitations as well. Inconsistent reporting in the medical record by medical staff could also contribute to missing data on bleeding cases. Selection bias was avoided by including 400 consecutive female patients in the study period.
Conclusion
We have demonstrated that the risk of hematuria requiring treatment after BTX-A injections is low in female patients on antithrombotic therapy. Thereby, BTX-A treatments are a low-risk surgical procedure, and we suggest that antithrombotic therapy should not be discontinued during the perioperative management of this patient group.
References
Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev. 2011;(12)CD005493.
Donze J, Rodondi N, Waeber G, Monney P, Cornuz J, Aujesky D. Scores to predict major bleeding risk during oral anticoagulation therapy: a prospective validation study. Am J Med. 2012;125:1095–102.
Gharacholou SM, Becker RC. Hemostasis and thrombosis in older adults. J Thromb Thrombolysis. 2009;27:249–51.
Halvorsen S, Mehilli J, Cassese S, et al. ESC guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J. 2022;43:3826–924.
Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). Rev Esp Cardiol (Engl Ed). 2022;75:429.
Izzo C, Carrizzo A, Alfano A, et al. The impact of aging on cardio and cerebrovascular diseases. Int J Mol Sci. 2018;19:481.
Kanthabalan ADC. Guideline for stopping anticoagulants prior to urological procedures. J Clin Urol. 2017;11:271–9.
Dansk Selskab for Trombose og Hæmostase. Available from: https://dsth.dk/. Accessed 21 February 2023
Ehren I, Volz D, Farrelly E, et al. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study. Scand J Urol Nephrol. 2007;41:335–40.
Flynn MK, Amundsen CL, Perevich M, Liu F, Webster GD. Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol. 2009;181:2608–15.
Kuo HC. Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity. J Urol. 2007;178:1359–63.
Mensah EE, Toia B, Nguyen L, et al. Intravesical onabotulinumtoxinA injections in patients on antiplatelet and anticoagulation therapy. Neurourol Urodyn. 2021;40:1829–33.
Truzzi JC, Lapitan MC, Truzzi NC, Iacovelli V, Averbeck MA. Botulinum toxin for treating overactive bladder in men: a systematic review. Neurourol Urodyn. 2022;41:710–23.
Park BE, Bae MH, Kim HJ, et al. Perioperative outcomes of interrupted anticoagulation in patients with non-valvular atrial fibrillation undergoing non-cardiac surgery. J Yeungnam Med Sci. 2020;37:321–8.
Douketis JD, Spyropoulos AC, Duncan J, et al. Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant. JAMA Intern Med. 2019;179:1469–78.
Weimar C, Cotton D, Sha N, et al. Discontinuation of antiplatelet study medication and risk of recurrent stroke and cardiovascular events: results from the PRoFESS study. Cerebrovasc Dis. 2013;35:538–43.
Kristensen SD, Knuuti J, Saraste A, et al. ESC/ESA guidelines on non-cardiac surgery: cardiovascular assessment and management: the joint task force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J. 2014;35:2383–431.
Mar PL, Familtsev D, Ezekowitz MD, Lakkireddy D, Gopinathannair R. Periprocedural management of anticoagulation in patients taking novel oral anticoagulants: review of the literature and recommendations for specific populations and procedures. Int J Cardiol. 2016;202:578–85.
Dimitropoulos K, Omar MI, Chalkias A, Arnaoutoglou E, Douketis J, Gravas S. Perioperative antithrombotic (antiplatelet and anticoagulant) therapy in urological practice: a critical assessment and summary of the clinical practice guidelines. World J Urol. 2020;38:2761–70.
Shah S, Urtecho M, Firwana M, et al. Perioperative management of antiplatelet therapy: a systematic review and meta-analysis. Mayo Clin Proc Innov Qual Outcomes. 2022;6:564–73.
Mantz J, Samama CM, Tubach F, et al. Impact of preoperative maintenance or interruption of aspirin on thrombotic and bleeding events after elective non-cardiac surgery: the multicentre, randomized, blinded, placebo-controlled, STRATAGEM trial. Br J Anaesth. 2011;107:899–910.
Culkin DJ, Exaire EJ, Green D, et al. Anticoagulation and antiplatelet therapy in urological practice: ICUD/AUA review paper. J Urol. 2014;192:1026–34.
Chen D, Liu G, Xie Y, Chen C, Luo Z, Liu Y. Safety of transrectal ultrasound-guided prostate biopsy in patients receiving aspirin: an update meta-analysis including 3373 patients. Medicine (Baltimore). 2021;100:e26985.
Konishi T, Washino S, Nakamura Y, et al. Risks and complications of transurethral resection of bladder tumors in patients receiving antiplatelet and/or anticoagulant therapy: a retrospective cohort study. BMC Urol. 2017;17:118.
Nikolakopoulos I, Spyropoulos AC. Heparin bridging therapy for patients on chronic oral anticoagulants in periprocedural settings. Semin Thromb Hemost. 2020;46:26–31.
Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015;373:823–33.
Kuo HC, Liu FL, Chen JT, Cherng YG, Tam KW, Tai YH. Thromboembolic and bleeding risk of periprocedural bridging anticoagulation: a systematic review and meta-analysis. Clin Cardiol. 2020;43:441–9.
Pollack Jr CV. Coagulation assessment with the new generation of oral anticoagulants. Emerg Med J 2016;33:423–30.
Funding
Open access funding provided by Royal Library, Copenhagen University Library The study was funded by the research council at Herlev and Gentofte University Hospital and the Department of Gynecology and Obstetrics, Herlev and Gentofte University Hospital. The funding sources played no role in the study’s design, conduct, analysis, or reporting.
Author information
Authors and Affiliations
Contributions
M. El Issaoui: project development, data collection, manuscript writing; S. Elissaoui: data collection, manuscript writing; M. Elmelund: project development, manuscript writing; N. Klarskov: project development, data collection, manuscript writing.
Corresponding author
Ethics declarations
Conflicts of interest
None.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
El Issaoui, M., Elissaoui, S., Elmelund, M. et al. Bleeding risk in female patients undergoing intravesical injection of onabotulinumtoxinA for overactive bladder: a Danish retrospective cohort study. Int Urogynecol J 34, 2581–2585 (2023). https://doi.org/10.1007/s00192-023-05579-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00192-023-05579-1